Unknown

Dataset Information

0

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

ABSTRACT:

SUBMITTER: Herbst RS 

PROVIDER: S-EPMC5847342 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst Roy S RS   Redman Mary W MW   Kim Edward S ES   Semrad Thomas J TJ   Bazhenova Lyudmila L   Masters Gregory G   Oettel Kurt K   Guaglianone Perry P   Reynolds Christopher C   Karnad Anand A   Arnold Susanne M SM   Varella-Garcia Marileila M   Moon James J   Mack Philip C PC   Blanke Charles D CD   Hirsch Fred R FR   Kelly Karen K   Gandara David R DR  

The Lancet. Oncology 20171120 1

<h4>Background</h4>EGFR antibodies have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that EGFR copy number by fluorescence in-situ hybridisation (FISH) can identify patients most likely to benefit from these drugs combined with chemotherapy and we aimed to explore the activity of cetuximab with chemotherapy in patients with advanced NSCLC who are EGFR FISH-positive.<h4>Methods</h4>We did this open-label, ph  ...[more]

Similar Datasets

Unknown Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
| S-EPMC4072123 | biostudies-literature
Unknown Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin.
| S-EPMC8959569 | biostudies-literature
Unknown A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
| S-EPMC6179372 | biostudies-literature
Unknown Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer.
| S-EPMC11909920 | biostudies-literature
Unknown Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
| S-EPMC3418968 | biostudies-literature
Unknown Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer.
| S-EPMC12541879 | biostudies-literature
Unknown PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
| S-EPMC4881367 | biostudies-literature
Unknown BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
| S-EPMC4669379 | biostudies-literature
Unknown IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
| S-EPMC8948406 | biostudies-literature
Genomics NCTN: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (S0819)
| PRJNA1306687 | ENA